Colorectal Cancer

Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.

Cured Meats, Nitrates, and Cancer Risk: Why Food Source and Processing Matter

From bacon and hot dogs to deli meats, cured meat products contain chemical compounds that increase the risk of cancer.

Colorectal Cancer Management

Colorectal Cancer Prevention

Colorectal Cancer and Organ Preservation

What is Colorectal Cancer?

What Causes Colorectal Cancer?

Colorectal Cancer Prognosis

Colorectal Cancer Diagnosis

Microbial Dysbiosis and Colorectal Cancer

Colorectal Cancer Symptoms

Colorectal Cancer Pathogenesis

Latest Colorectal Cancer News and Research

Stony Brook-developed cancer drug advances to human clinical trials

A promising new cancer chemotherapeutic agent from a taxane class of natural compounds – anti-cancer agents designed to block cell division and trigger the programmed cell death to treat sold tumors – originally developed by researchers at Stony Brook University has entered human clinical trials.

6 Nov 2026

Rising colorectal cancer rates prompt earlier routine screening recommendations

Forty-five is the new 60 – at least when it comes to colonoscopies. That may not be the party you look forward to, but it could save your life. According to the Cancer Research Institute, 1 in 5 colorectal cancers are diagnosed in patients under age 55, making what was once thought of as an older person's disease one of the fastest-growing cancers in young people.

5 Nov 2026

Protein DUSP4 prevents immune cell exhaustion in colorectal cancer

The immune system has powerful cells that can recognize and destroy cancer, but this ability can gradually wane when the cells reside within a tumor.

4 Nov 2026

Blood may reveal signs of gut-related disease that stool samples miss

In a study of 193 participants, researchers found that blood-based short-chain fatty acid profiles distinguished colorectal cancer, celiac disease, obesity, and healthy controls with 95% accuracy, compared with 59% for stool-based measurements. Combining blood and stool profiles increased accuracy to 97%, suggesting that circulating microbial metabolites may offer valuable diagnostic information, although larger studies are needed to validate the findings.

3 Nov 2026

Aspirin fails to prevent recurrence after surgery for colorectal cancer liver metastases

Colorectal cancer is one of the most common cancers in Norway, which also has one of the highest incidence rates in the world.

2 Nov 2026

New study reveals why colorectal cancer is more aggressive in youth

Dana-Farber Cancer Institute researchers, along with Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, and the Broad Institute, have uncovered biological clues to why colorectal cancer can behave more aggressively in younger people.

29 Oct 2026

Machine learning models predict common cancer risks using routine health data

Machine learning models using routinely collected health information, such as blood tests, medical history and lifestyle factors, could help identify people at higher risk of several common cancers, according to an international study reported at the ESMO Congress 2026.

27 Oct 2026

Friends play a direct role in encouraging regular cancer screening

Friends may play a direct role in whether people keep up with cancer screening regularly, while family influence appears to operate more through knowledge and attitudes towards screening, according to new research by Singapore Management University's (SMU) Center for Research on Successful Ageing (ROSA).

26 Oct 2026

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.

26 Oct 2026

Study identifies potential new ways to treat the most common type of bowel cancer

Major new research published today identifies potential new ways to treat the most common type of bowel cancer in Ireland.

23 Oct 2026

BGI Genomics smarter stool testing detects colorectal cancer across Latin America

BGI Genomics' COLOTECT® addresses colorectal cancer in LATAM through innovative non-invasive screening, enhancing early detection and treatment efficiency.

From BGI Genomics 22 Oct 2026

Not all ultra-processed foods show the same cancer risk

Ultra-processed foods show varied associations with colorectal cancer, underscoring the need for precise research on diet quality and cancer risk factors.

20 Oct 2026

CSHL researchers find way to make immunotherapy effective against colorectal cancer

Colorectal cancer has become the leading cause of cancer-related death for people under 50. Its most common forms generally aren't treatable, either through conventional means like chemotherapy or newer immunotherapy drugs.

14 Oct 2026

Researchers uncover how metastatic colorectal cancer evades immune attack

Researchers at Hokkaido University, in collaboration with an international team of scientists led by the University of South Florida Health and Tampa General Hospital, have uncovered an important mechanism behind immune evasion in metastatic colorectal cancer (mCRC).

13 Oct 2026

Scientists studied diet and lung cancer in 95,612 adults. One eating pattern stood out

A prospective study of 95,612 U.S. adults found that those with the highest sulfur microbial diet scores had a 23% higher adjusted lung cancer incidence hazard and a 19% higher lung cancer-related mortality hazard than those with the lowest scores. However, the associations weakened after accounting for overall dietary quality and competing causes of death, and the findings do not establish a causal relationship.

13 Oct 2026

FDA approves atezolizumab combination for stage III colon cancer with deficient DNA mismatch repair

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

9 Oct 2026

Lynch syndrome patients rarely use aspirin for cancer prevention

According to international studies, taking Acetylsalicylic acid daily can protect people with Lynch syndrome from developing colorectal cancer - even at low doses. Researchers from the University Hospital Bonn (UKB), the University of Bonn, and the Center for Integrated Oncology (CIO) Bonn, in collaboration with the self-help organization SemiColon, have now found that these scientific findings have so far been insufficiently incorporated into clinical practice.

9 Oct 2026